cell construct to collagen, and this expression does not interfere with cell proliferation (Fig. 1C and D) . Additionally, ACSA expression did not disrupt collagen-dependent intracellular signaling, as the phosphorylation patterns in transduced cells expressing the ACSA-GFP construct, in the presence of Dox, were similar to that seen in transduced NIH/3T3 cells, cultured in the absence of Dox, in which the expression of the ACSA-GFP was blocked ( Fig. 2) . At Day 2, the average migration distance of cells, without expression of the ACSA-GFP, was 0.28 mm (±0.02), while the average migration distance for cells expressing this construct was 0.12 mm (±0.03) (Fig. 3) . The corresponding values after three days of incubation were 0.5 mm (±0.01), and 0.3 mm (±0.01), respectively. The difference in migration distances was statistically significant for both days (p<0.0001). No difference in migration was observed between non-transduced NIH/3T3 control cells cultured in the presence or the absence of Dox (not shown), and the migration patterns of these groups were similar to those patterns seen in transduced cells cultured in the absence of Dox. Discussion: Expression of the ACSA-GFP construct enhances the ability of the cell construct to bind collagen without adversely impacting cellular proliferation. Additionally, the ACSA did not disrupt collagen-dependent intracellular signaling, or the ability of engineered cells to contract collagen gels. These findings suggest that this artificial anchor does not interfere with cellular binding via native collagen-specific receptors. The dynamics of contraction did not differ between the group of cells expressing the ACSA-GFP; and when expression was inhibited, it appears that the ACSA-GFP does not actively participate in gel contraction. Considering that collagen-specific Integrins and DDR1 recognize well defined specific sites within the collagen I triple helical domain and that the ACSA targets the distant α2Ct region, the collagen gel contraction assays indicates the high binding specificity of the novel collagen I-binding construct that does not interfere with the binding of native receptors. The novel collagen specific cell-anchoring system proposed here may have a wide-ranging impact on developing improved repair processes of collagen I-rich tissues, including tendon, ligament, bone, intervertebral disc, and skin. Moreover, a successful ACSA approach to deliver and retain cells can potentially provide a blueprint for the development of additional cell-delivery methods that can target other elements within the extracellular matrix, including laminin and fibronectin. Another potential advantage of this concept is that the engineered cells can be designed to carry a therapeutically relevant molecule to the site of injury, with controlled delivery. Thus, ACSA-expressing cells can be engineered to produce a growth factor that enhances the repair process, allowing the precise binding and retention of therapeutic cells at the injury site, with controlled release of therapeutic growth factors. Future experiments in preclinical models may determine the clinical utility of the proposed method to improve the site-specific delivery and retention of therapeutic cells. Significance: Fibrosis after tendon injury remains a challenging clinical problem, and current molecular strategies for improving tendon healing are limited by inefficient and non-specific therapeutic delivery. This novel cellular construct enables the controlled expression of collagen-targeting anchors at the surface of therapeutic cells, enhancing cellular attachment and retention to collagen-rich sites, without disrupting cell proliferation or collagen-dependent intracellular signaling. Potential benefits may include the specific targeting and controlled binding of therapeutic cells to the injury site, the reduced dispersion of cells into surrounding tissue, and enhanced tendon healing with improved safety and efficacy.
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